Cancer

News

Can in vivo imaging deliver the full potential of immunotherapy

German biotech CatalYm raises €50 million for GDF-15 inhibit...

CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15).

News

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated p

News

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

News

After two decades, NICE begins consultation on drug assessme...

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics.

News